
News
All series
All News


Faricimab is now the first and only FDA-approved drug to target two distinct pathways known to cause retinal disease that may lead to vision loss.

Ahead of World Neglected Tropical Diseases (NTD) Day on Jan. 30, Alemayehu Sisay, MD, MPH, country director for Orbis Ethiopia, discusses efforts and progress the organization has made in treating patients with NTDs and how to get involved in recognizing World NTD Day.

Research also highlights the top factors that lead to care, which can be used to improve parents' uptake of sight-saving surgery for their children.

The annual national conference in February will offer 3 intensive days of business management curricula, COPE-approved clinical education, staff training and high-profile guest speakers.

Significant differences were found in the pupillary diameters between when the virus was active and 3 months later, Turkish investigators report.

Manufacturing of the omicron-specific vaccine has already begun.

Positive one-year results of Genentech’s phase III trials analyzing faricimab for treatment of wet AMD and DME were released today.

Saudi Arabian investigators have determined that Vitamin D levels are not protective against the severity or the outcomes of COVID-19 infections.

Genetics researchers reported identifying a genetic link to the biologic mechanisms responsible for COVID-19-related loss of smell or taste.

Alcon has launched the latest addition to its European dry eye products portfolio: Systane Complete Preservative-Free Lubricant Eye Drop, available in an easy-to-use, multi-dose bottle, the company announced last week.

Signs of the SARS-CoV-2 virus in human ocular tissues samples post-mortem were found to be low in samples considered suitable for corneal recovery and transplantation.

Acute corneal endothelial rejection is a possibility soon after either the first or second dose of the COVID-19 messenger RNA (mRNA) vaccine (Moderna), according new research.

Transitions Optical's Diversity Advisory Board members share how eyecare professionals can incorporate diversity, equity and inclusion in their lives and careers.

ASCENT, RegenXBio’s Phase III clinical trial conducted in partnership with AbbVie, is expected to enroll patients in the United States and Canada, with pivotal trials expected to support BLA submission for RGX-314 in 2024.

Dr. Kerry Gelb speaks with Dr. Jay M. Hainie in the second part of their discussion on diabetes of the eye!

Electronic health records may be the future of practice management.

The 25th annual event was originally scheduled for January 16-19.


Exciting news from OYE Technology!

Clark Chang, OD, MSA, MSc, FAAO, shares why he wish he'd known more about the versatility of the optometric field before starting out in the optometric field.

One doctor's experience leads to key takeaways in ensuring quality care for all patients.

Marc R. Bloomenstein OD, FAAO, and Mile Brujic, OD, FAAO, share the key takeaways from their presentations at EyeCon ’21.

Two EyeCon ’21 faculty panelists highlight their presentation, “Visions of the Future: Contact Lenses of Today and Tomorrow.”

An increase in popularity of the use of handheld electronics is resulting in changes in the postural and behavioral patterns of device users, as well as significant differences between presbyopes and non-presbyopes and between genders.

See our latest poll results

In-person event inspires excellence in eye care

Disrupted vaccination routines in children to blame

From the Chief Optometric Editor



